Background

Scientists have learned that a build-up of amyloid plaque in the brain is neurotoxic (which means it is bad for brain cells) causing brain cells to degenerate and die leading to subsequent memory loss/dementia. We are conducting a study with a medication which blocks the production of new amyloid protein to see if it can reduce the formation of amyloid plaque in the brain and whether it can either stop or slow the loss of memory.

Criteria to participate

Some of the criteria patients must satisfy to participate are:

  • Age between 50 and 85 years old
  • Have a study partner (i.e. someone who is with you for 8 hours or more each week and would be willing to come to the study center about twice a year with you)
  • Demonstrate a mild level of memory loss when tested
  • Have a positive PET (brain scan) for amyloid plaque
  • Able to have an MRI scan (that is no metal in your head or upper torso)
  • Taking a stable dose of Alzheimer’s medications for 3 months or more
  • No history of stroke in the past 12 months

About the Study

Once the study criteria are met, the patient will receive either the study medication or a placebo for the duration of the 24 month study; neither the patient nor the doctor will know which is assigned. The study medication is a tablet which is taken once a day. During the study, brain MRI scans are done once yearly and a amyloid PET scan is performed at the beginning and end of the study. Once the main study is completed, all patients are then offered real medication (no placebo) until the medication is approved for use on the market. There is no cost to the patient for medical care provided in the study nor for any of the scans, memory testing, or medication.

Current Studies

We are currently conducting the following study with a medication which seeks to block production of amyloid protein used in forming brain plaque

Study

Sponsor

Study Medication

NCT Number

Study Status

Mission AD

Eisai

Elenbecestat

NCT03036280

Enrollment open

You may use the NCT number to learn more about the study we are conducting by going to clinicaltrials.gov and entering the number in the search bar.